This report separates four commercial layers:
| Layer | What belongs in it | How the buyer should use it |
|---|---|---|
| National medicine market | Pharmaceutical purchases, estimated net spending and manufacturer revenue | Establish scale and direction; do not sum incompatible measures |
| Patient access market | Cash-pay offers, insurance cost sharing and manufacturer-linked dispensing | Model affordability and the patient journey |
| Clinic-controlled expenditure | Stock purchases where applicable, service contracts, integrations, shipping and internal handling | Identify spending the organization can actually negotiate |
| Supporting infrastructure | Pharmacy services, prescription routing, financing, acquisitions and manufacturing investment | Monitor counterparties and potential changes in access arrangements |
These are the desk’s analytical categories, not interchangeable accounting measures. The scope includes obesity-focused GLP-1 medicines and related incretin treatments such as tirzepatide; diabetes products appear only where they help explain the wider market.
Evidence labels used below: reported figure; survey estimate; manufacturer-reported estimate; analyst calculation; announced commitment; and not publicly established. Annual data refer to 2025 unless stated otherwise. Recent financial observations cover Q3 2026. Live offer pages were checked on November 17, 2026.
Explore the table row by row
A working view of the research
National medicine market
- What belongs in it
- Pharmaceutical purchases, estimated net spending and manufacturer revenue
- How the buyer should use it
- Establish scale and direction; do not sum incompatible measures
Sources cited on this page
See the section’s source register for the research context.
Section sources →